Abstract |
The observed effects on the symptoms of fibromyalgia of daily oral administration of 5 mg of the 5-HT3 receptor antagonist, tropisetron, for 10 days, could be maintained or exceeded with intravenous administration of only 2 mg of the formulation. Following a single i.v. injection of 2 mg tropisetron, a more rapid and profound reduction in pain was achieved than with 5 mg oral tropisetron per day. In individual cases, patients who had previously experienced no reduction in pain from 10 days of 5 mg oral tropisetron daily responded to i.v. therapy. A more favourable and persistent effect on pain, combined with a simultaneous significant improvement in various vegetative and functional symptoms was achieved with five days treatment with 2 mg tropisetron i.v. per day. The results outlined and the possibility for rapid improvements with drug treatment of fibromyalgia should be confirmed in randomised, placebo controlled trials.
|
Authors | W Müller, T Stratz |
Journal | Scandinavian journal of rheumatology. Supplement
(Scand J Rheumatol Suppl)
Vol. 113
Pg. 59-62
( 2000)
ISSN: 0301-3847 [Print] Norway |
PMID | 11028834
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Indoles
- Serotonin Antagonists
- Tropisetron
|
Topics |
- Administration, Oral
- Adult
- Aged
- Dose-Response Relationship, Drug
- Female
- Fibromyalgia
(drug therapy, physiopathology)
- Humans
- Indoles
(administration & dosage, adverse effects, therapeutic use)
- Injections, Intravenous
- Male
- Middle Aged
- Pain Measurement
- Serotonin Antagonists
(administration & dosage, adverse effects, therapeutic use)
- Tropisetron
|